Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
February 9, 2016
- PeptiDream Joins Hands with Shionogi, 5th Japanese Partner
February 8, 2016
- Takeda Expands ADC Collaboration with US Startup Mersana
February 5, 2016
- FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction
February 5, 2016
- Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary
February 5, 2016
- BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
February 5, 2016
- Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
February 5, 2016
- Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
February 4, 2016
- Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ
February 4, 2016
- Mitsubishi Tanabe to Shed 10-Plus % of Japan Workforce
February 4, 2016
- Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE
February 4, 2016
- Sovaldi, Harvoni Haul in Nearly US$1.9 Billion in Japan: Gilead
February 4, 2016
- Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
- Belsomra Most Promoted Drug for GPs for 6 Straight Month: Anterio
February 3, 2016
- Seikagaku, Kaken Call Off Artz Development for Expanded Indication
February 3, 2016
- Sakigake-Designated NS-065 Now in PI/II: Nippon Shinyaku
February 3, 2016
- Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
February 3, 2016
- J-TEC Files Skin-Derived Cell Sheet JACE for Giant Pigmented Nevus
February 2, 2016
- Pola Pharma to Take Over GSK’s Marketing Authorization for Acne Drug Duac
February 2, 2016
- Eisai Gets Japan, Asia Rights to HDAC Inhibitor
February 2, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…